A Safety, Tolerability and Pharmacokinetic Study of cP12 in Adults With Up To 10% Total Body Surface Area Burns

NCT06814717 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

6

Enrollment

OTHER

Sponsor class

Conditions

Thermal Burns

Interventions

DRUG: cP12

Sponsor

Neomatrix Therapeutics, Inc.

Collaborators

[object Object]